Cyclooxygenase 2 inhibitors and thrombogenicity production: comment on the article by Crofford et al.
Sperling
R
R
Braunstein
N
N
Melin
J
J
Reicin
A
A
D000068579:Celecoxib; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects*; D013927:Thrombosis / Q000139:chemically induced*
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib